Tag Archives: cellular therapies

FDA Guidance, Cellular Therapy for Cardiac Disease

FDA Guidance, Cellular Therapy for Cardiac Disease.

Full Text Here

The FDA, are issuing this guidance to provide you, sponsors who are developing cellular therapies for the treatment of cardiac disease, with recommendations on the design of preclinical and clinical studies, and on the chemistry, manufacturing, and controls (CMC) information to include in an Investigational New Drug application (IND) for cellular theracardiac disease. This guidance also provides recommendations regarding the information thyou should submit on the product’s delivery system. Sponsors should consult with FDA concerning the regulatory pathway for the use of cell selection devices.

For assistance with Biotechnology Development Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

New Draft FDA Guidance on Somatic Cell Therapy for Cardiac Disease

The FDA CBER (Centre for Biologics Evaluation and Research) has released some draft guidance for industry. it is intended to provide sponsors who are developing cellular therapies for the treatment of cardiac disease, with recommendations on the design of preclinical and clinical studies and on the Chemistry Manufacturing and Controls information needed for IND’s (Investigational New Drug Applications), for cellular therapies aimed at cardiac disease. The guidance also provides recommendations regarding the information that you should submit on the product’s delivery system.

The Background to this guidance is expanded upon!

Despite advances in medical and surgical therapies, heart disease remains a major cause of morbidity and mortality. There is an increasing number of patients with significant morbidity despite optimal medical management. Cardiac cellular therapies have emerged as a field designed to advance the treatment of heart disease through the regeneration of cardiac tissues.

There has been much debate about how to interpret differing data and theories on the mechanism of action of cell therapies in cardiovascular disease. This guidance appears to be an attempt to set some standards in the design of these trials.

If you want to read the full guidance click here.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug  evelopment target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida consultants freestrategyconsultation 515x64 New Draft FDA Guidance on Somatic Cell Therapy for Cardiac Disease

Free Strategy Consultation - Biotech Pharma Regualtory